Affilogic is a biotech company specialized in the discovery and development of a novel class of proprietary small size protein therapeutics - NanofitinsÎ, for the treatment of CNS, cancer and Infectious Disease.
Affilogic has exclusive and worldwide rights to technology, which is based on the research in protein engineering at the Pasteur Institute and the CNRS.
Affilogic is looking for new partners for custom generation of Nanofitins as next generation biopharmaceuticals. Affilogic has designed Nanofitins against 40+ targets, including a wide range of circulating antigens, membrane receptors for inhibition / modulation (GPCR, ion channels) and complex entities (Virus-like Particles, bacteria, whole cells).
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/affilogic” connections=”true” suffix=””]
Affilogic proprietary NanofitinsÎ variants are obtained through engineering the wild-type Sac7d proteins, and are around 20 times smaller than a monoclonal antibody. NanofitinÎovercomes antibodies limitations and allows generation of local delivery formulations, single-gene multi-specific molecules and NanofitinÎ-Drug-Conjugates.
In Sep 2016, Affilogic enter into Research Collaboration with Takeda Pharmaceutical Company Limited to explore using Affilogics proprietary NanofitinsÎ platform in therapies targeting the central nervous system.
Under the terms of the agreement, Affilogic will receive undisclosed upfront payment and research funding, sales milestone payments and royalties by Takeda
Recover your password.
A password will be e-mailed to you.